Company Overview and News
Stocks were indicated to open marginally higher on Friday, but not so much that the direction of this day looked set. U.S. equity indexes remain near all-time highs at a time that most international markets are not close to their highs. One issue that stands out to U.S. investors is that they have seen less upside from buying on market pullbacks than in prior years. Investors also need to consider how they want to have their investments positioned for the rest of 2018.
WFCNP YELP ADBE WMT WFC GLW ANGI COST GRUB DHI DNKN TRI
Investors focused on the Computer and Technology space have likely heard of Angie's List (ANGI - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Computer and Technology peers, we might be able to answer that question.
TiVo Corporation (TIVO - Free Report) was a big mover last session, as the company saw its shares rise more than 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $11.40 to $13.00 in the past one-month time frame.
ANGI BGSF TIVO
Facebook (FB - Free Report) is reportedly working on a feature named Things In Common that will let strangers connect with each other on the basis of shared interests. The feature will enable public discussion forums on the platform to become more effective as it will get people from the same locality or educational institutions connected, with the common information between two participants highlighted.
MTCH FB EXPI ANGI
Good day and welcome to the ANGI Homeservices Q2 2018 Results Conference Call. At this time, I'd like to turn the conference over to CEO, Glenn Schiffman. Please go ahead, sir.
IAC/InterActiveCorp (NASDAQ:IAC) stock was trending upward as the company reported its latest quarterly earnings results on Wednesday, which included a profit and revenue beat.
MTCH IAC ANGI
GOLDEN, Colo., Aug. 08, 2018 (GLOBE NEWSWIRE) -- ANGI Homeservices (NASDAQ: ANGI) posted its second quarter financial results on the investor relations section of its website at ir.angihomeservices.com. As announced previously, the company will host a conference call tomorrow, Thursday, August 9, 2018, at 8:30 a.m. Eastern Daylight Time (EDT) to answer questions regarding its second quarter results.
2018-07-18 globenewswire - 1
GOLDEN, Colo., July 18, 2018 (GLOBE NEWSWIRE) -- After the close of market trading on Wednesday, August 8, 2018, ANGI Homeservices (NASDAQ:ANGI) will post its second quarter results on the investor relations section of the company’s website at ir.angihomeservices.com. On Thursday, August 9, 2018 at 8:30 a.m. Eastern Daylight Time (EDT), ANGI Homeservices will host a conference call to answer questions regarding its second quarter results.
The futures traded down again Thursday morning, and it appears that the back and forth trading on Wednesday wore down investors. Once again, the trade and tariff issues were cited as the main reason. Oil jumped again, sparked by a big drop in crude inventories, closing up over 2.5%. With summer vacations in full swing and Americans hitting the road in record numbers to celebrate the fourth of July, you can bet there may be some added pain at the pump.
CBS CBS.A ANGI FLXN RF LMNR CBS.WD ATSG CRM BF.B BF.A BFA TRI CPV MS
2018-05-29 investorplace - 1
Facebook, Inc. (NASDAQ:FB) keeps expanding its reach. The most recent development was the announcement Wednesday of a Facebook home service product. While it might not be a game changer for Facebook stock, it certainly is worth noting.
MTCH FB AMZN GOOGL ANGI PYPL GOOG WMT
2018-05-10 seekingalpha - 1
Good day, and welcome to the IAC and ANGI Homeservices Report First Quarter 2018 Results Conference Call.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to ANGI / Angie's List, Inc. on message board site Silicon Investor.
as of ET